Last reviewed · How we verify
NCT06098495: FIB_CARIPLO
Looking for a Blood Epigenetic Signature to Predict Female Infertility
trial testing search for epigenetic profile of infertility in Female Infertility in 1,456 participants. Currently enrolling.
16 October 2026
Quick facts
| Lead sponsor | Università Vita-Salute San Raffaele |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,456 |
| Start date | 16 October 2023 |
| Primary completion | 16 October 2026 |
| Estimated completion | 16 October 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- search for epigenetic profile of infertility
Conditions studied
- Female Infertility — all drugs for Female Infertility →
Sponsor
Università Vita-Salute San Raffaele — full company profile →
Who can join
Adults 18 to 43, female only, with Female Infertility. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present research project aims to study the DNAm mechanisms underlying the reduction of fertility due to the progressive depletion of oocyte quality. Specifically, our project aims to build an epigenetic clock for MGCs by using outcomes that are certainly related to female fertility. The validation of such findings will be carried out on peripheral blood in order to guarantee its non-invasiveness and allow for any clinical transferability. In order to identify a blood epigenetic signature able to predict female infertility, we planned to explore the problem from different points of view by conducting several studies in different settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06098495
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Female Infertility
Currently open trials in the same condition.
- NCT07500337 — Day-4 Embryo Defragmentation: Blastocyst Rate and clInical Outcomes · NA · recruiting
- NCT07394530 — Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS · NA · recruiting
- NCT07066267 — Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT) · NA · recruiting
- NCT06896747 — Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study · Phase 1, PHASE2 · recruiting
- NCT06921395 — Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulat · Phase 4 · recruiting
Other Università Vita-Salute San Raffaele trials
Trials by the same sponsor.
- NCT07274384 — Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial · Phase 2 · not yet recruiting
- NCT06716502 — A New Portable Device for Non-invasive Ventilatory Support · NA · recruiting
- NCT05982496 — 18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer · NA · not yet recruiting
- NCT06487091 — Platelet Function and Impella Support · recruiting
- NCT06538155 — Technological and Patient-tailored Innovations for Maximizing Effectiveness of Cardiac Arrest Resuscitation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06098495 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Università Vita-Salute San Raffaele
- Last refreshed: 24 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06098495.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing